Navigation Links
Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus
Date:3/11/2008

BOSTON, March 11 /PRNewswire/ -- Replikins, Ltd. has announced development of a chemically synthesized vaccine specific to a Taura Syndrome virus structure based on its patented Replikins(TM) technology. When the vaccine was administered orally to shrimp, 91% survived a challenge by the lethal Taura virus. The specificity of the protective effect was established in control groups by chemically blocking the active regions in the vaccine, and as a result the protective effect was lost in these control groups. The effectiveness of this vaccine, and its rapid production cycle (7 days), represent an important proof of concept for developing vaccines against a range of rapidly replicating high lethality virus outbreaks.

For counteracting emerging infectious disease, early detection and rapid response are critical. Replikin contributions to date are both in early detection and rapid response: 1) Advance warning previously was not possible until it was found in H5N1 influenza that an increase in the virus replikin concentration signalled one year in advance that the outbreak was coming, and indicated the country in which this would occur (FluForecast(TM), Indonesia). 2) The production of vaccines by other methods has required 3 to 12 months, by which time the epidemic may have come and gone, or the vaccine effectiveness reduced or lost because the target changed due to mutation. In contrast, the replikins vaccine found effective here was manufactured synthetically in 7 days.

Viruses lethal to shrimp have been responsible for large losses to aquaculture worldwide. Replikins is forming a division to focus on these viruses. The company is also pursuing development of synthetic vaccine products based on replikin epitopes, Syntopes(TM), for the control of fish hemorrhagic viruses and other lethal aquatic microorganisms,

Contact: Replikins Ltd., 38 The Fenway, Boston MA 02215. email: sbogoch@replikins.com Tel: 646-320-5910 http://www.Replikins.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
2. Vaccinogens New Anti-Cancer Vaccine Commercially Available in Europe This Year
3. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
4. Combination vaccine protects monkeys from ebola and Marburg viruses
5. Nasal Vaccine for Smallpox Confers High Levels of Immunity Without Safety Risks
6. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
7. GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral)
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Vaccinex Antibody Licensed to GlaxoSmithKline
10. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
11. NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract research, ... improve patient outcomes and quality of life, will now be offering its impurity ... to new regulatory requirements for all new drug products, including the finalization of ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
Breaking Biology Technology:
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):